SBIR Phase I: Digital Barcode Etched Assayable Micro (BEAM) Bead for Rare Biomolecules Separation and Purification

SBIR 第一阶段：用于稀有生物分子分离和纯化的数字条形码蚀刻可分析微珠 (BEAM)

• 批准号: 0638279
• 负责人: Jian Tajbakhsh
• 金额: --
• 依托单位: MAXWELL SENSORS INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0638279&HistoricalAwards=false
• 关键词: SBIR; Phase; Digital; Barcode; Etched

This Small Business Innovation Research (SBIR) Phase I project focuses on developing a process to detect mutations that combines the technologies of bar-coded beads, microfluidic, and nucleic acid hybridization for the separation and purification of multiple biomarkers in bodily fluids. The presence of biomarkers or mutant circulating DNA in blood can be a diagnostic and prognostic indicator, making body fluids potentially useful for diagnostics and patient monitoring. The proposed technology allows for the selective enrichment of ultra rare mutant alleles from a multiplexed amplification assay. As it has been shown that there are biomarkers, or tumor DNA circulating in a very small quantity in the blood of cancer patients, this technology may allow the development of automated blood tests for early detection of minimal residual diseases in high-risk patients.

该小型企业创新研究 (SBIR) 第一阶段项目的重点是开发一种检测突变的方法，该方法结合了条形码珠、微流体和核酸杂交技术，用于分离和纯化体液中的多种生物标志物。血液中生物标志物或突变体循环 DNA 的存在可以作为诊断和预后指标，使体液可用于诊断和患者监测。所提出的技术允许从多重扩增测定中选择性富集超稀有突变等位基因。 由于癌症患者血液中存在极少量的生物标记物或肿瘤 DNA，因此该技术可能有助于开发自动化血液检测，以便及早发现高危患者的微小残留疾病。